2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediators
2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL
2013
Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma
Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma. American Journal Of Hematology 2013, 88: 606-611. PMID: 23619945, PMCID: PMC3902049, DOI: 10.1002/ajh.23463.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBody Mass IndexCase-Control StudiesDNA RepairDNA-Binding ProteinsExodeoxyribonucleasesFemaleGenotypeHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMiddle AgedPolymorphism, GeneticRecQ HelicasesRisk FactorsUbiquitin-Protein LigasesWerner Syndrome HelicaseX-ray Repair Cross Complementing Protein 1Xeroderma Pigmentosum Group D ProteinConceptsBody mass indexNon-Hodgkin lymphomaDNA repair pathway genesCT/TTMass indexNHL riskPopulation-based case-control studyRisk of NHLDiffuse large B-cell lymphomaGT/TT genotypesLarge B-cell lymphomaAC/CCT-cell lymphomaCase-control studyB-cell lymphomaConnecticut womenTT genotypeGG genotypePathway genesLymphomaCommon genetic variationWomenRiskSignificant interaction
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapy
2009
Alcohol consumption and non-Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2009, 4: 101-109. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaNon-Hodgkin lymphomaAlcohol consumptionHazard ratioNHL subtypesNHL survivalNon-Hodgkin lymphoma survivalCox proportional hazards modelLarge B-cell lymphomaDisease-free survivalBetter overall survivalKaplan-Meier methodModerate alcohol drinkersProportional hazards modelB-cell lymphomaLower death ratesIntroductionEpidemiological studiesFree survivalOverall survivalNHL patientsAlcohol drinkersIncident casesMethodsA cohortAlcohol drinkingDLBCL patients